Mycophenolate Interruption Restores Anti-SARS-CoV-2 Vaccine Immunogenicity in Unresponsive Liver Transplant Recipients.
SARS-CoV-2 infection
anti-SARS-CoV-2 vaccine
liver transplantation
mycophenolate mofetil
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
27 Jun 2023
27 Jun 2023
Historique:
received:
12
05
2023
revised:
19
06
2023
accepted:
24
06
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
The fourth dose of anti-SARS-CoV-2 vaccine slightly improved the humoral response among previously seronegative liver transplant (LT) recipients. Mycophenolate (MMF) treatment worsens the vaccination response. This study aimed to evaluate whether temporary MMF interruption might improve the immunogenicity of the fourth anti-SARS-CoV-2 BNT16b2 vaccine dose in nonresponsive LT recipients. LT recipients negative for anti-spike glycoprotein-specific immunoglobulin G receptor-binding domain (s-RBD) antibodies after the third vaccine dose were enrolled. Anti-SARS-CoV-2 spike-specific T-cell responses were measured before and 2 months following the fourth vaccine dose, and anti-SARS-CoV-2 s-RBD antibodies also 6 months thereafter. MMF was suspended two weeks before and after vaccination. Five LT recipients were enrolled. After a mean of 78 days after vaccination, all patients tested positive for anti-SARS-CoV-2 s-RBD antibodies. The mean antibody titer was 8944 UI/mL. The positive antibody response was maintained during a mean of 193 days of follow-up. Three patients developed a positive T-cell response. Two patients (one positive for T-cell response) developed a self-limited SARS-CoV-2 infection. Suspending MMF prior to the fourth dose of the anti-SARS-CoV-2 mRNA vaccine seems feasible and safe. This procedure could restore vaccine-induced immunogenicity in a large portion of previously nonresponsive LT recipients.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
The fourth dose of anti-SARS-CoV-2 vaccine slightly improved the humoral response among previously seronegative liver transplant (LT) recipients. Mycophenolate (MMF) treatment worsens the vaccination response. This study aimed to evaluate whether temporary MMF interruption might improve the immunogenicity of the fourth anti-SARS-CoV-2 BNT16b2 vaccine dose in nonresponsive LT recipients.
METHODS
METHODS
LT recipients negative for anti-spike glycoprotein-specific immunoglobulin G receptor-binding domain (s-RBD) antibodies after the third vaccine dose were enrolled. Anti-SARS-CoV-2 spike-specific T-cell responses were measured before and 2 months following the fourth vaccine dose, and anti-SARS-CoV-2 s-RBD antibodies also 6 months thereafter. MMF was suspended two weeks before and after vaccination.
RESULTS
RESULTS
Five LT recipients were enrolled. After a mean of 78 days after vaccination, all patients tested positive for anti-SARS-CoV-2 s-RBD antibodies. The mean antibody titer was 8944 UI/mL. The positive antibody response was maintained during a mean of 193 days of follow-up. Three patients developed a positive T-cell response. Two patients (one positive for T-cell response) developed a self-limited SARS-CoV-2 infection.
CONCLUSIONS
CONCLUSIONS
Suspending MMF prior to the fourth dose of the anti-SARS-CoV-2 mRNA vaccine seems feasible and safe. This procedure could restore vaccine-induced immunogenicity in a large portion of previously nonresponsive LT recipients.
Identifiants
pubmed: 37514981
pii: vaccines11071165
doi: 10.3390/vaccines11071165
pmc: PMC10383127
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Transplantation. 2022 Jul 1;106(7):1440-1444
pubmed: 35417115
Liver Int. 2023 Feb;43(2):452-461
pubmed: 35661561
Clin Mol Hepatol. 2022 Oct;28(4):890-911
pubmed: 36263669
JAMA Netw Open. 2021 Nov 1;4(11):e2136030
pubmed: 34817587
Transplantation. 2022 Jul 1;106(7):e338-e340
pubmed: 35426888
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2558-2566.e5
pubmed: 35850415
Am J Med. 2022 Feb;135(2):157-166
pubmed: 34508700
Transplantation. 2021 Dec 1;105(12):e280-e281
pubmed: 34428188
JAMA. 2021 May 4;325(17):1784-1786
pubmed: 33720292
Liver Int. 2022 Aug;42(8):1872-1878
pubmed: 35338550
J Clin Exp Hepatol. 2022 May-Jun;12(3):937-947
pubmed: 34975241
Transplantation. 2022 Sep 1;106(9):e413-e415
pubmed: 35655363
Transplantation. 2018 May;102(5):727-743
pubmed: 29485508
Infect Dis Clin North Am. 2023 May 2;:
pubmed: 37142511
Liver Transpl. 2023 Jan 1;29(1):114-117
pubmed: 36047916
Front Med (Lausanne). 2022 Jun 10;9:914424
pubmed: 35755078
Int J Biol Sci. 2022 Sep 21;18(15):5849-5857
pubmed: 36263175
J Hepatol. 2014 May;60(5):1075-89
pubmed: 24384327
Clin Res Hepatol Gastroenterol. 2020 Apr;44(2):126-134
pubmed: 31607643
Int J Mol Sci. 2022 Aug 24;23(17):
pubmed: 36076960
Vaccine. 2022 Oct 19;40(44):6404-6411
pubmed: 36184404
Viruses. 2022 Aug 12;14(8):
pubmed: 36016388
Ann Rheum Dis. 2022 Feb;81(2):293-295
pubmed: 34556484
Transplantation. 2023 Jun 13;:
pubmed: 37309028